| ●Editorial | Kuzuhara S | 369 | Full text | |
| ●Rare and Intractable Diseases Translational Research Conference 2014 Toward the New Horizon of Rare Disease－Present status and scope of innovation in the academic sector－ |
371-573 | Abstract | ||
| Organized by：Translational Research Informatics Center, Foundation for Biomedical Research and Innovation | ||||
| Program management for Research Project on Practical Application for Rare/Intractable Diseases, Research Project on Practical Application for Renal Diseases, and Research Project on Elucidation of Chronic Pain | Fukushima M | 376-83 | ||
| Opening remarks | Tahara K | 384-5 | ||
| Practical application of medical products from medical front－The PMDA’s challenge to the world－ | Kondo T | 386-8 | ||
| AMED: Mission and perspectives | Suematsu M | 389-93 | ||
| The present situation and the prospects of the activity of the NANBYO patients’ groups | Ito T | 394-7 | ||
| Trials for rare diseases－NCATS perspective－ | Kaufmann P | 398-413 | ||
| A multi-center, randomized, double-blind, placebo-controlled trial to
determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody | Tahara M | 414-7 | ||
| Investigator-initiated clinical trial of humanized anti-CCR4 antibody in HAM | Yamano Y | 418-21 | ||
| Development of disease-modifying therapy for multiple system atrophy | Tsuji S | 422-5 | ||
| Development of therapy for amyotrophic lateral sclerosis using HGF | Aoki M | 426-8 | ||
| Investigator-initiated HAL-HN01 clinical study for intractable rare neuromuscular diseases | Nakajima T | 429-33 | ||
| Discussion | 434-5 | |||
| Multicenter Lymphangioleiomyomatosis long term Sirolimus Trial for Safety (MLSTS) | Nakata K | 436-9 | ||
| Development and approval of effective therapeutics with minimum toxicity
for skin lesions of tuberous sclerosis complex | Kaneda M | 440-3 | ||
| N-acetylneuraminic acid replacement therapy for distal myopathy with rimmed vacuoles | Aoki M | 444-7 | ||
| Taurine supplemental therapy for the mitochondrial disease MELAS | Sunada Y | 448-9 | ||
| Development of therapeutic drug of Sodium Pyruvate (SP) for lactic acidosis associated with mitochondrial disorders | Koga Y | 450-3 | ||
| Discussion | 454-5 | |||
| Triglyceride deposit cardiomyovasculopathy－To overcome this intractable disease a day sooner－ | Hirano K | 456-9 | ||
| Development of myoblast sheet for children’s dilated cardiomyopathy | Sawa Y | 460-3 | ||
| Development and practice of the in situ induced regeneration therapy using
new oxime derivatives sustained-release formulation (YS-1402), aiming for life prognosis improvement and artificial heart device removal in cardiomyopathy patients with severe heart failure dilated | Miyagawa S | 464-8 | ||
| Nanoparticle-mediated drug targeting for the development of innovative
therapy against severe pulmonary arterial hypertension | Egashira K | 469-72 | ||
| Preclinical study of defected gene-transduced preadipocytes for patients with familial LCAT deficiency | Bujo H | 473-6 | ||
| Discussion | 477 | |||
| Investigator-initiated clinical trial of rituximab for thrombotic thrombocytopenic purpura | Miyakawa Y | 478-81 | ||
| Effects of Extracorporeal Shock Wave Therapy on the digital ulcers of Systemic Sclerosis | Ishii T | 482-6 | ||
| BCAA for treatment of underpowered muscles during glucocorticoid healing of polymyositis and dermatomyositis (BTOUGH) | Kohsaka H | 487-8 | ||
| Validation of safety and efficacy of OCH-NCNP for refractory Crohn’s disease | Kanai T | 489-92 | ||
| Investigator-initiated clinical trial of a novel oral drug for multiple sclerosis | Yamamura T | 493-4 | ||
| Discussion | 495-6 | |||
| Identification of novel biomarkers for diabetic nephropathy using lectin microarray | Wada J | 497-500 | ||
| Chemical library screening for WNK kinase signaling inhibitors | Uchida S | 501-3 | ||
| Design of the comprehensive health care system for chronic kidney disease
(CKD) based on the individual risk assessment by Specific Health Checkups | Watanabe T，Asahi K | 504-7 | ||
| Establishment of clinicopathological diagnoses and related biomarkers for diabetic nephropathy and nephrosclerosis | Wada T | 508-9 | ||
| Clinical trial for early detection of IgA nephropathy by novel pathogenetic biomarkers in medical checkup examinee with hematuria | Suzuki Y | 510-3 | ||
| Discussion | 514-5 | |||
| Pain perception in humans | Kakigi R | 516-22 | ||
| The translational research on chronic pain: The elucidation of pathogenesis and development of evaluation system from psychological, psychiatric and neuroimmunological aspects | Hosoi M | 523-7 | ||
| Translational research of cerebral mechanisms underlying pain chronification toward development of diagnosis and treatment methods | Kato F | 528-9 | ||
| Strategic and innovative project research for pathogenetic mechanism and
development of objective diagnostic criteria, severity score and total management system for fibromyalgia | Matsumoto Y | 530-3 | ||
| Discussion | 534 | |||
| Comprehensive genome sequencing for diagnoses and elucidation of molecular basis of neurological diseases | Tsuji S | 535-9 | ||
| Establishment of integrated diagnostic center for hereditary myopathies | Nishino I | 540-4 | ||
| Networking of genome and epi-genome analysis in pediatric and obstetric diseases | Matsubara Y | 545-8 | ||
| Whole exome sequencing center for genetic intractable diseases | Matsumoto N | 549-52 | ||
| Genome analysis of cardiovascular disease aiming drug discovery | Takashima S | 553-4 | ||
| Trans-omics analysis of rare diseases in Japanese | Matsuda F | 555-9 | ||
| Development of disease-modifying therapy from a nation-wide cohort with
bio-resources studies for sporadic amyotrophic lateral sclerosis patients | Sobue G | 560-1 | ||
| Hereditary retinal diseases: Sample collection and elucidation of disease causing genes | Iwata T | 562-5 | ||
| Discussion | 566-70 | |||
| Closing remarks | Kuzuhara S | 571-3 | ||
| ●Consolidated strategic meeting for cancer research and management in disruptive innovation era | 575-605 | Abstract | ||
| Organized by：Ministry of Education, Culture, Sports, Science and Technology | ||||
| Consolidated strategic meeting on development of next-generation cancer molecular-targeted therapy | Fukushima M | 577-80 | ||
| Organizing a nation-wide genome-based medicine network in Japan | Ohtsu A | 581-8 | ||
| An activity and proposal for genome-based cancer treatment | Ohtsu A | 589-93 | Abstract | |
| The trend in global strategy of clinical development for new drug: Therapeutic small molecule and antibody | Doi T | 594-600 | ||
| Recent clinical development of four innovative anticancer drugs invented in Japan | Kojima S | 601-5 | ||
| ●Articles | ||||
| Approach to objective evaluation of clinical instructors giving the lecture on “Residents’ Bedside Manner” | Abe Y，Soejima M， Itabashi K | 607-11 | Abstract | |
| Revision of the CIOMS Ethical Guidelines for Biomedical Research－Global health and value of research－ | Kurihara C，Saio T | 613-28 | Full text | |
| ●Instructions for authors［Japanese］&［English］ | 629-37 | Full text | ||
| ●Editor’s note | Tsubaki H | 639 | Full text | |
| ［Electronic publications only］ | ||||
| ●Translation | ||||
| Regulatory framework for approval of PET drug in Korea: A survey report | Kurihara C，Inoue T （trans. by Kurihara C） | 641-53 W107-W119 | Full text | |